Bio Farma Targets Rp 3 T Revenue This Year

INDUSTRY.co.id - Jakarta- PT Bio Farma (Persero) targets revenues in 2017 of around Rp 3 trillion with vaccine production estimated at up to 3.1 billion doses per year.

"With a vaccine production of around 3.1 billion doses per year, Bio Farma remains one of the world's leading vaccine companies, with revenues reaching 14 percent over 2016 of Rp2.7 trillion," said Bio Farma Marketing Director M. Rahman Rustan, during a press conference at the Indonesia Business Development Expo 2017 (IBDExpo), at the Jakarta Convention Center on Wednesday (07/20/2017)

According to Rahman, revenue growth is driven by high market demand for vaccines that in the last five years continue to be at a high level of about 3 billion doses per year.

He explains, currently Bio Farma producing 14 types of vaccines. Twelve of them have met the standards set by the Food and Drug Supervisory Agency (BPOM) and the World Health Organization (WHO), among others, the polio vaccine, measles, hepatitis B, BCG, vertusis, diphtheria, tetanus, influenza B and two other types of vaccines are not registered with WHO because they are used domestically.

In addition to the vaccine, Bio Farma also produces four types of serum.

According to Rahman, from revenue of around Rp 3 trillion, as many as 60 percent of which is the contribution of export markets. "Once we make sure the vaccine for the country is filled, and then exported," he said.

The need for a national vaccine includes about 5 million babies per year, about 12 million school-aged children and 23 million women of childbearing age.

With the production of 14 types of vaccines and four serums, then Bio Farma became one of the largest vaccine companies in the world.

"More than 142 countries have been using Bio Farma products, especially developing countries, with 49 countries including the Organization of Islamic Cooperation (OIC)," he said.